Michael Barbella, Managing Editor04.22.22
The first patient has been enrolled in a study evaluating a digital health solution for kidney transplant patients.
Cibiltech's trial, “Clinical Impact of the iBox as an early Intervention tool” is a prospective randomized controlled study to assess the use of an artificial intelligence-based algorithm designed to predict allograft survival in kidney transplant patients. The study is the first of its kind in Europe, according to the company.
“The CIBIL study aims to provide clinical and health economic evidence to allow further deployment of Predigraft in Europe. It opens the way to a large adoption of AI-based medical device softwares,” stated Stephane Tholander, CEO of Cibiltech.
Predigraft is a CE-marked class IIa medical device offering physicians and hospitals an easy-to-use platform that simplifies access to data and decision making. Predigraft embeds the iBox algorithm, a unique AI-based technology predicting individual long term kidney allograft survival.
“We are excited to start recruitment in the CIBIL study,” said Professor Carmen Lefaucheur, transplant nephrologist at Saint-Louis Hospital.
”Following promising preliminary results, we are now looking forward to seeing the clinical benefits of using the iBox as an early intervention monitoring tool for kidney transplanted patients,” added Professor Alexandre Loupy, Head of the Paris Transplant Group.
Predigraft was created based on the iBox technology, an algorithm developed by the Paris Transplant Group (University of Paris), which gives the probability that the graft will still be functional at three, five, and seven years after evaluation by the a healthcare professional.
Cibiltech develops artificial intelligence-based software medical devices, offering its solutions to patients, healthcare professionals and to the pharmaceutical industry. Cibiltech's ambition is to build the distribution platform for algorithms to prevent organ failures.
Cibiltech's trial, “Clinical Impact of the iBox as an early Intervention tool” is a prospective randomized controlled study to assess the use of an artificial intelligence-based algorithm designed to predict allograft survival in kidney transplant patients. The study is the first of its kind in Europe, according to the company.
“The CIBIL study aims to provide clinical and health economic evidence to allow further deployment of Predigraft in Europe. It opens the way to a large adoption of AI-based medical device softwares,” stated Stephane Tholander, CEO of Cibiltech.
Predigraft is a CE-marked class IIa medical device offering physicians and hospitals an easy-to-use platform that simplifies access to data and decision making. Predigraft embeds the iBox algorithm, a unique AI-based technology predicting individual long term kidney allograft survival.
“We are excited to start recruitment in the CIBIL study,” said Professor Carmen Lefaucheur, transplant nephrologist at Saint-Louis Hospital.
”Following promising preliminary results, we are now looking forward to seeing the clinical benefits of using the iBox as an early intervention monitoring tool for kidney transplanted patients,” added Professor Alexandre Loupy, Head of the Paris Transplant Group.
Predigraft was created based on the iBox technology, an algorithm developed by the Paris Transplant Group (University of Paris), which gives the probability that the graft will still be functional at three, five, and seven years after evaluation by the a healthcare professional.
Cibiltech develops artificial intelligence-based software medical devices, offering its solutions to patients, healthcare professionals and to the pharmaceutical industry. Cibiltech's ambition is to build the distribution platform for algorithms to prevent organ failures.